Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2024)
32 slides from Cyclopharm's shareholder meeting presentation, May 27, 2024
Slide 1: Cyclopharm 2024 Annual General Meeting
For personal use only CYCLOPHARM 2024 Annual General Meeting 27 May 2024 1
Slide 2: Safe Harbour Statement
Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect For personal use only to the anticipated future financial performance of Cyclopharm
Slide 3: Welcome
For personal use only Welcome Mr David Heaney 3
Slide 4: Chairman's Address
For personal use only CHAIRMAN’S ADDRESS Mr David Heaney 4
Slide 5: Technegas around the world
Technegas® around the world For personal use only Technegas® was introduced to the medical community in 1986 Technegas® generators are available in 65 countries via a combination of direct and distributor sales models Over 4.7 million patient procedures to date 5
Slide 6: A World Leading Diagnostic Imaging Company
A World Leading Diagnostic Imaging Company Recovery in FY 2023 continued from initial COVID-19 impact in primary country markets with 1 record sales of $26.3m. (Technegas sales $14.43m up 5.6% - Third-party sales $11.91m up 29.3% compared to 2022) For personal use only Continued underlying profitabi
Slide 7: Managing Director's Address
For personal use only MANAGING DIRECTOR’S ADDRESS Mr James McBrayer 7
Slide 8: Financial Highlights
$26.34 million - an increase of 15.1% Sales Revenue For personal use only Third Party Distribution $11.91 million of third‐party distribution revenue, an increase of 29.3% 2023 Net Loss After Tax $4.70 million loss including US-FDA related expenses Financial USFDA Expenses $3.49 million Reversal of
Slide 9: 2023 Operating Highlights
Sales increased 5.6% to $14.43 m For personal use only Technegas Third Party Distribution $11.91 million of third‐party distribution revenue, , an increase of 29.3% 2023 Regulatory Renewals All regulatory renewals in existing 64 country Operating Indication Expansion markets maintained Continued pro
Slide 10: Largest addressable market globally: US pulmonary embolism opportunity
Largest addressable market globally 600K Nuclear Medicine Ventilation Procedures p.a. in the USA* For personal use only 15%/600k Cyclopharm estimates 4,000,000 pulmonary embolism procedures in the 1 USA per annum (15% Nuclear Medicine / 85% CTPA) ~600,000 Nuclear Medicine Ventilation procedures repr
Slide 11: US Customer Demand Established
US Customer Demand Established 136 Proposals and Contracts representing over 400+ locations For personal use only 1 Over 420 expressions of interest already received 2 6 Technegas systems have been installed and are delivering Revenue; 6 further sites under contract 3 Additional 40 sites linked to t
Slide 12: USA Commercialisation Pathway
Clinical Regulatory Key Opinion Leaders engaged Australian Site Manufacturing Approved Medical Affairs Director Recruited USFDA Approval Granted Clinical Affairs Director Recruited State Pharmaceutical Wholesale Licenses being Recruit Chief Medical Officer 2025. Granted R&D Programs
Slide 13: Total value creation opportunity
Total value creation opportunity Exponential Growth Opportunity Over The Next Decade For personal use only USA PE Pulmonary Embolism: Timeline Market Share Market size Horizon 1 – Full displacement of existing 1 nuclear medicine tests for PE 0 - 5 years 15% US$90m Horizon 2 – Commence converting CTP
Slide 14: Indication Expansion: The Importance, Urgency & Opportunity Beyond PE
Indication Expansion – The Importance, Urgency & Opportunity Beyond PE For personal use only 1 Lung Disease in 2019 accounted for 6 million deaths worldwide (12% of all deaths) 2 COPD and Lower Respiratory Infections and Lung Cancer will be the 3rd, 4th and 6th largest causes of death by 2030. “Over
Slide 15: Beyond PE applications of V/Q SPECT(/CT)
Beyond PE applications of V/Q SPECT(/CT) >US$1.1bn global For personal use only market size* Diagnosis and Advanced approach Preoperative Preoperative Planning Use of alternate follow-up of to phenotyping chronic assessment of assessment of radiation therapy isotopes to make Pulmonary airways diseas
Slide 16: Beyond Pulmonary Embolism Initiatives Underway
Beyond Pulmonary Embolism Initiatives Underway 7 Cyclopharm sponsored Beyond PE clinical trials Hunter Medical Research Institute (Newcastle, AU): Diagnosis and response to therapy in severe asthma and COPD1 For personal use only 1 100 Patient Study * 100% Recruited * Study Published6, Woolcock Inst
Slide 17: Upcoming Milestones and Growth Catalysts
Technegas formal commercial launch at the First North American Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference since FDA approval June 2024 For personal use only Market expansion beyond Cyclopharm’s 65 Upcoming established country markets Milestones and Pass Through status
Slide 18: Cyclopharm Investment Case
CYCLOPHARM INVESTMENT CASE For personal use only Profitable and First in Class USFDA Approval Granted Recurring Revenue Technegas Product expansion Growing MedTech Established Gold Standard Set to quadruple the size From single patient Indications Beyond PE into Underlying business (ex-USA) Propriet
Slide 19: Formal Business
For personal use only FORMAL BUSINESS Mr David Heaney 19
Slide 20: 2024 AGM – Formal Business
2024 AGM – Formal Business Resolutions Financial – (b) Remuneration Report For personal use only 1 2 Election of Mr John Wigglesworth as Director 3 Share Buy-back 4 Approval of Loan Share Plan 20
Slide 21: Resolution: Remuneration Report
CYC AGM 2024 Resolutions For personal use only 1(b) That the Remuneration Report as set out in the Annual Report of the Company for the financial year ended 31 December 2023 be adopted. Resolution For Against Discretionary Abstain Remuneration Report 23,716,701 84,566 37,988,457 155,923 Questions? 2
Slide 22: Resolution: Election of Mr John Wigglesworth
CYC AGM 2024 Resolutions For personal use only 2 That, for the purposes of ASX Listing Rule 14.4 and for all other purposes, Mr John Wigglesworth, being eligible and having consented to act, be elected as a Director of the Company. Resolution For Against Discretionary Abstain Election of Mr John Wig
Slide 23: Resolution: Share Buy-back
CYC AGM 2024 Resolutions For personal use only 3 That pursuant to and in accordance with section 257C(1) of the Corporations Act, as amended, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant announcement to the ASX, the on-market buy-back of
Slide 24: Resolution: Approval of Loan Share Plan
CYC AGM 2024 Resolutions For personal use only 4 That the Cyclopharm Loan Share Plan (LSP), a summary of which is set out in the Explanatory Statement, be approved for the purposes of ASX Listing Rule 7.2 (Exception 13), sections 200E, 259B(2) and 260C(4) of the Corporations Act and for all other pu
Slide 25: 2024 AGM – Proxy Summary
2024 AGM – Proxy Summary For personal use only Resolution For Against Discretionary Abstain 1(b) Remuneration Report 23,716,701 84,566 37,988,457 155,923 2 Election of Mr John Wigglesworth as Director 26,309,179 56,673 38,119,900 152,000 3 Share Buyback 26,443,759 84,716 38,099,277 10,000 4 Approval
Slide 26: Business Q&A
For personal use only 26 BUSINESS Q&A
Slide 27: Thank You
For personal use only T H A N K YO U 27
Slide 28: Appendix
For personal use only Appendix 28
Slide 29: Technegas Aerosol for Inhalation
Technegas® Aerosol for Inhalation Functional imaging of Oxygen distribution within the lung For personal use only Technegas® is composed of 99mTc cores encapsulated within layers of graphite to form individual hexagonal plate-like particles.1-2 Technegas is manufactured by heating Technetium-99m in
Slide 30: Overview of the Technegas Plus System, Patient Consumables and package insert
Overview of the Technegas® Plus System, Patient Consumables and package insert USA INDICATIONS AND USAGE For personal use only TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m- labeled carbon inhalation aerosol (Technegas Aerosol), a radi
Slide 31: Track Record - Rapid adoption of Technegas
Track Record - Rapid adoption of Technegas® The Canadian Case Study - a strong indicator of USA acceptance For personal use only Canada is Cyclopharm’s largest single country 1 market to date Technegas® is market leader for diagnosing PE 2 and is nearing 100% nuclear medicine market share 3 Xe-133 r
Slide 32: 2023 Trading Highlights and Underlying Business
2023 Trading Highlights and Underlying Business An established global nuclear medicine company For personal use only Cyclopharm 2023 Trading Highlights Cyclopharm operating revenues over time Technegas Third party sales 30.0 Technegas Sales increased 5.6% to $14.4m 26.3 25.0 Third Party $11.9m of th